Neogen Corporation last reported quarterly results on Oct 6, 2026, for Q1 FY2027 (the quarter ended Aug 31, 2026): revenue of $222.8 million (+6.5% year over year) and diluted EPS of -$0.05. It usually reports 36–60 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q2 FY2027, the quarter ending around Nov 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–60 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 6, 2026
36 days after quarter end
|
Q1 FY2027
ended Aug 31, 2026
|
223
+6.5%
|
-12
-132.8%
|
-0.05
-129.4%
|
|
Jul 30, 2026
60 days after quarter end
|
Q4 FY2026
ended May 31, 2026
|
225
-0.1%
|
-11
+98.2%
|
-0.05
+98.1%
|
|
Apr 9, 2026
40 days after quarter end
|
Q3 FY2026
ended Feb 28, 2026
|
211
-4.4%
|
-17
-56.0%
|
-0.08
-60.0%
|
|
Jan 8, 2026
39 days after quarter end
|
Q2 FY2026
ended Nov 30, 2025
|
225
-2.8%
|
-16
+96.5%
|
-0.07
+96.7%
|
|
Oct 9, 2025
39 days after quarter end
|
Q1 FY2026
ended Aug 31, 2025
|
209
|
36
|
0.17
|
|
Jul 29, 2025
59 days after quarter end
|
Q4 FY2025
ended May 31, 2025
|
226
-4.8%
|
-612
-11249.6%
|
-2.82
-11229.9%
|
|
Apr 9, 2025
40 days after quarter end
|
Q3 FY2025
ended Feb 28, 2025
|
221
-3.4%
|
-11
-439.1%
|
-0.05
-400.0%
|
|
Jan 10, 2025
41 days after quarter end
|
Q2 FY2025
ended Nov 30, 2024
|
231
+0.7%
|
-456
-12985.2%
|
-2.10
-10400.0%
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NEOG (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- MI
- Headquarters
- Lansing, MI
- SEC filer status
- Large accelerated filer
- SEC CIK
- 711377
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.